|
Oncolab provides the FDA approved AMAS blood test, helping health care professionals to diagnose cancer, and to follow up during treatment. In studies of more than 8,000 patients, the AMAS® Test was found to be 96% accurate and unique for its diverse use as a diagnostic tool regarding all non-terminal cancers. In some cases, the AMAS® test detected cancer 1 to 19 months before clinical detection.
These tests indicate with great accuracy (99% specificity and 96% sensitivity) if there is cancer active anywhere within your body.
AMA is the antibody to Malignin, a 10,000 Dalton polypeptide which has been found to be present in most malignant cells regardless of cell type or location (refs.1 to 8). Unlike tests such as CEA , which measure less well-defined antigens whose serum levels tend to be inconstant but elevated late in the disease, the AMAS test measures a well-defined antibody whose serum levels rise early in the course of the disease. In some cases, the AMAS test has been positive (elevated) early , i.e. 1 to 19 months before clinical detection.
... the AMA (Anti-Malignin Antibody) is elevated almost regardless of the site or cell type of the malignancy; that is, AMA is a general transformation antibody, not just for one particular kind of cancer. For sera shipped overnight, false positives are 5% and false negatives 7%
(3,315 double-blind tests of patients and controls, refs. 4, 6 and 8).
Anti-Malignin Antibody is elevated in 93-100% of cases in which active non-terminal malignancy is the clinico-pathological diagnosis; overall asymptomatic (’false’) positives are 5% in sera kept shipped overnight (refs.4-8). AMA is normal in 96% of cancer patients who no longer have evidence of disease (refs.4,6). Within-run, inter-technician-same-lab, and inter-lab variability are low, as reported in the Smith-Kline study(ref.6).
If your doctor is not familiar with the test and does not have a shipping kit, please call and we can send a free kit. The kit contains reprints of scientific papers on the test a requisition form, and all supplies for drawing and sending a blood serum sample. The kit includes a Styrofoam packing box and silicone-free test tubes, as well as step-by-step instructions for the lab. The only other requirements are a centrifuge and a local supplier of dry ice for shipping (dryicedirectory.com). Your doctor should receive the results within 72 hours of our receiving the serum sample.
San Antonio, TX (PRWeb) May 3, 2007 --
At the NAAS annual conference, Oncolab presented the AMAS antibody-based test for cancer and described aspects of the current healthcare environment which make the test so important. The presentation emphasized the impact that the AMAS test can have on early detection and effective treatment of recurrences or first occurrences of cancer. A preventative approach to cancer, coupling the AMAS test with powerful new imaging and diagnostic techniques that are now increasingly in use, should be a powerful driver to help contain and reduce healthcare costs.
The AMAS test, a diagnostic test which tests for circulating levels of a specific antibody, provides a unique tool for monitoring cancer patients in remission. The antibodies bind specifically to a 10,000 molecular weight protein found in a wide range of cancers. Because it monitors an aspect of the body's immune response to cancer, rather than cancer antigens or cancer cells in the bloodstream, the AMAS test is especially accurate early in the recurrence or first occurrence of cancer, when clinical signs of the disease may not be evident or may just be emerging.
Patients in remission after successful cancer therapy, or a healthy normal population, generally have normal circulating levels of the antibody assayed in the test. AMAS's low false positive rate, shown to be 5% in double-blind clinical studies, means that elevated results on the test are highly suspicious for a recurrence or unrelated new occurrence of cancer, and warrant further clinical investigation. While the AMAS test is not generally useful in advanced cancer, its high sensitivity and specificity early in the disease allow it to be used to improve early detection of first occurrence and recurrence of the disease.
The emergence of new imaging techniques such as MRI and CT scans provides a powerful complement to the AMAS test's ability to flag early cancer occurrence and recurrence. With these tools, which are now becoming affordable and widely used, it is often possible to find small malignancies, leading to early and effective clinical treatment. Survival rates for cancers found early are generally much better than for those found later in the disease, and death rates, treatment costs, and productivity losses can be minimized.
Information and Kits
Please contact us if you have any questions about the test. We can provide you with a free kit that includes a requsition form to be signed by your doctor, all materials needed to prepare a sample for shipment, and a packet of reprints of scientific articles about the test.
http://www.oncolabinc.com/AMASrequisition.pdf
Cancer Test., noted on the MiracleMineral site.
Here is something your doctor will never tell you, there has been a medical test for cancer that is 99% effective for more than 25 years. It is more effective, less dangerous and cheaper than all other medical cancer tests. It’s called AMAS cancer test. You don’t have to go to a doctor; the test is available on the Internet. The cost is $165. The kit is free, you take a smear of your own blood and send it in and pay when the results are ready. The test is for specific cancer antibodies that will be present. ..
The AMAS cancer test listed above gives anyone a fantastic advantage.
One can do a test, use the MMS for several weeks or a month and then do a second test to see how much improvement has taken place or to see if any improvement has happened at all.
|